Three myostatin inhibitors—bimagrumab, roledumab, and trevogrumab—are entering the pipeline alongside new GLP-1s.

Three myostatin inhibitors, bimagrumab, roledumab, and trevogrumab, are coming down the pipeline to preserve muscle during caloric deficit.

“Myostatin inhibitors. There are three that are coming down the pipeline. There is one called bimagrumab, which is owned by Lilly. That is going to bind to the peanut butter to myostatin's jelly, which is called activin. And then you have roledumab and trevogrumab.”